Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MediGene
Biotech
BioNTech jumps into PRAME game, paying $29M for T-cell therapy
BioNTech, flush with COVID-19 cash, is paying Medigene $29 million for a preclinical T-cell receptor prospect designed to treat solid tumors.
Nick Paul Taylor
Feb 22, 2022 7:10am
Medigene loses CMO after slashing staff, blood cancer program
Mar 19, 2021 9:35am
Medigene shares sag as it axes TCR-T blood cancer drug
Jan 28, 2021 8:45am
Ramaswamy's latest 'vant' debuts with Medigene TCR partnership
Apr 4, 2019 11:17am
Bluebird adds targets, $500M in milestones to Medigene TCR pact
May 14, 2018 9:05am
Medigene gets OK for first trial of T-cell receptor therapy
Feb 21, 2018 9:25am
